PBL Signs License Agreement with Thermo Fisher
News Dec 03, 2015
Plant Bioscience Limited (PBL) has announced that it has entered into a licensing agreement that grants Thermo Fisher Scientific a world-wide, non-exclusive license to the Baulcombe patents for use in the field of research reagents and kits.
PBL’s Managing Director Dr Jan Chojecki, stated: “We are very pleased to enter into this agreement with Thermo Fisher, a global leader in research reagents based on RNA interference and detecting gene silencing. Thermo Fisher has an excellent product portfolio in this important and growing area of science. We look forward to working with other partners through our non-exclusive licensing strategy in agricultural, research, diagnostic and therapeutic commercial applications. We are pleased to be able to make non-exclusive licenses available on reasonable commercial terms to assist our partners in all areas of RNAi.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.